The Lesinski Laboratory is focused on understanding the interactions between the immune system and cancer. opinions are my own. #immunotherapy#GICancer
Very nice resource paper in @Cancer_Cell that enables correlation of cell type specific expression data with survival in #PancreaticCancer.
cell.com/cancer-cell/fulltex…
Takes TCGA type datasets based on bulk RNA to the next level. Interactive web tool (ctPANDA) allows facile queries.
Shirish Gadgeel, MBBS, FASCO, a nationally recognized thoracic oncologist and clinical researcher, joins @EmoryMedicine and Winship as professor and vice chair for clinical research in the Department of Hematology and Medical Oncology. 🔗 brnw.ch/21x2CQW
The 2026 SITC Election closes tomorrow at 11:59 p.m. EDT! SITC regular and emeritus members (current in dues) can vote at sitcancer.org/get-involved/2…
Learn about 2026 SITC At-Large Director candidate, Gregory B. Lesinski, PhD, MPH (Winship Cancer Institute of Emory University). Read about Dr. Lesinski: sitcancer.org/get-involved/2…
Welcome to the 2026 Cholangiocarcinoma Foundation Annual Conference! 💚
We will be together for the next 3 days to learn, share and collaborate. #ccfac26
#sitc election voting is now open!!!
Don’t delay shaping the future of #immunotherapy with your vote.
Feel free to throw a vote my way for “at large director”, but there is no losing as ALL Candidates are amazing!
The 2026 SITC Election is now open! SITC members are electing the society’s next Vice President, Secretary/Treasurer and three At-Large Directors. The election closes on Friday, May 15 at 11:59 p.m. EDT. sitcancer.org/get-involved/2…
I am humbled to be on the #sitc ballot as an at large candidate to support this #immunotherapy driven organization! Would love your vote on May 1st to help @sitcancer
The #SITC election opens May 1. The Vice President candidate who receives the most votes will begin their two-year term in 2027 before ascending to the role of SITC President in 2029. Read the biographies and platform statements of this year’s candidates: sitcancer.org/get-involved/2…
Thank you @curecc for highlighting our poster describing FGFR2b as a promising cell surface target in cholangiocarcinoma at #AACR26! We hope to expand tx options for CCA patients. I am very grateful for the for the mentorship of @ShuklaSachet and @JavleMilind!
It's encouraging to see continued progress in cholangiocarcinoma research at #AACR2026. 🔬
We are grateful for the researchers behind this work who are committed to driving meaningful progress for patients. 💚 #cureCCA
#AACR26☝🏽A question that’s lingered for years:
dMMR/MSI-H➡️immunotherapy… but can we induce it?
Can pMMR/MSS tumors be converted➡️dMMR/MSI-H—and made responsive to IO?
Remarkably, this team has done it.✅ 🤯
🎯 NP1867 🔆🔅
@CD_AACR@OncoAlert@AACRaacrjournals.org/cancerdisco…
The @NIH has ended continuous submission. The new policy gives two extra calendar weeks from the submission deadline if you have a study section or SEP as a reviewer within 4 weeks before or after a regular deadline, or serve on an NIH advisory council
grants.nih.gov/grants/guide/…
1/n
Setidegrasib the first-in-human, first-in-class, KRAS G12D-targeted protein degrader #TPD
Our KRAS G12D degrader study is now published in the New England Journal of Medicine @NEJMnejm.org/doi/full/10.1056/NE…
A new way to target KRAS G12D - one of the most common oncogenic drivers across cancers.
Fortunate to have Dr. Francisca Vasquez #depmap as the keynote for our @WinshipAtEmory@universityofga 2026 Cancer Research Summit! A tremendous example of impactful research!